A5065087590- Sarcoma Diagnosis and Treatment
- Vascular Tumors and Angiosarcomas
- Colorectal Cancer Treatments and Studies
- Cardiac tumors and thrombi
- Bone Tumor Diagnosis and Treatments
- Cancer Treatment and Pharmacology
- Gastric Cancer Management and Outcomes
- Oral and Maxillofacial Pathology
- Hepatocellular Carcinoma Treatment and Prognosis
- Soft tissue tumor case studies
- Lymphoma Diagnosis and Treatment
- Musculoskeletal synovial abnormalities and treatments
- Neuroendocrine Tumor Research Advances
- Gastrointestinal Tumor Research and Treatment
- Cutaneous lymphoproliferative disorders research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Neurofibromatosis and Schwannoma Cases
- Lung Cancer Treatments and Mutations
- Occupational and environmental lung diseases
- CAR-T cell therapy research
- Soft tissue tumors and treatment
- Cancer and Skin Lesions
- Breast Cancer Treatment Studies
- Pancreatic and Hepatic Oncology Research
- Breast Lesions and Carcinomas
Hospital of Prato
2015-2025
Nuovo Ospedale di Prato
2016-2024
Media Working Group
2024
Azienda Ospedaliera San Camillo-Forlanini
2023
Azienda di Rilievo Nazionale ed Alta Specializzazione
2023
Harefield Hospital
2023
Ospedale Versilia
2023
Istituti di Ricovero e Cura a Carattere Scientifico
2023
Fondazione IRCCS Istituto Nazionale dei Tumori
2012-2023
Azienda Usl Toscana Centro
2009-2023
In Brief Objective/Background: The GONO-FOLFOXIRI regimen improved the rate of R0 secondary resection metastases in initially unresectable metastatic colorectal cancer. objective this study was to evaluate long-term outcome resected patients and impact FOLFOXIRI on perioperative morbidities, mortality, chemotherapy induced hepatotoxicity. Patients Methods: Overall, 196 with cancer were treated 2 phase II 1 III trial. This associated an elevated response (70.4%) 37 (19%) could undergo a...
Several studies have suggested that KRAS somatic mutations may predict resistance to cetuximab- and panitumumab-based treatments in metastatic colorectal cancer (CRC) patients. Nevertheless, most experiences were conducted on samples from primaries. The aim of this study was evaluate the grade concordance terms status between primaries related metastases.We analyzed codon 12 13 formalin-fixed sections 107 CRC metastases. Eight pairs excluded analysis because low amount tumor tissue available...
In a randomized trial with median follow-up of 18.4 months, 6 months induction chemotherapy three-drug regimen comprising 5-fluorouracil (by continuous infusion)-leucovorin, irinotecan, and oxaliplatin (FOLFOXIRI) demonstrated statistically significant improvements in response rate, radical surgical resection metastases, progression-free survival, overall survival compared fluorouracil-leucovorin irinotecan (FOLFIRI).From November 14, 2001, to April 22, 2005, we enrolled 244 patients...
Denosumab, a fully human monoclonal antibody directed against RANKL, has recently been introduced in the treatment strategy of giant cell tumour bone (GCTB). Aim this study was to investigate phenotypical modifications induced by denosumab series 15 GCTB.The tumours were characterised for histone 3.3 mutations, and studied immunohistochemically RANK, SATB2 RUNX2 expression, as well proliferative activity angiogenesis.Nine 11 investigated presented mutation H3F3A, 2 these which analysis...
We explore the pattern of late recurrence (LR) in solitary fibrous tumor (SFT), focusing on histopathologic characteristics, clinical presentation and patients (pts) outcome. Clinical records all pts with confirmed pathologic diagnosis SFT treated at our Institution from 2005 to 2011 were reviewed. analysed data who relapsed ≥10 years after initial diagnosis. A total 14 identified. The primary site origin was pleura (5 pts), pelvis (4 head neck (3 pts) retroperitoneum (2 pts). Primary a...
Denosumab is a monoclonal RANKL antibody, which was originally introduced for the treatment of osteoporosis and bone metastases from solid tumors, but more recently has been used giant cell tumor (GCTB). In GCTB, denosumab as single agent in patients with inoperable tumors; it also before surgery some aim to downstage facilitate joint-preserving procedure (curettage) rather than resection. However, few studies are available evaluating benefits risks latter indication.(1) Does preoperative...
This study aimed to review the activity of cytotoxic chemotherapy in patients with inflammatory myofibroblastic tumors (IMTs) treated at nine European sarcoma reference centers.Patients any age, histologically proven IMT, anthracycline-based methotrexate plus/minus vinorelbine/vinblastine (MTX-V) or other chemotherapeutic regimens between 1996 and 2018 were retrospectively reviewed. Diagnosis was confirmed local level by an expert pathologist. Response assessed investigators RECIST v1.1....
Treatment options for patients with metastatic synovial sarcoma are limited. Over recent years, trabectedin has emerged as an effective agent advanced soft tissue sarcomas resistant to anthracyclines and ifosfamide. The aim of this retrospective analysis was study the efficacy in subgroup sarcomas. A carried out on treated at four European reference centers within Italian Rare Cancer Network between 2000 2013. Radiological response, progression-free, overall survival, well serious unexpected...
•This is the largest reported series of advanced CCS patients treated with systemic therapy.•The activity sarcoma-type therapy poor and modest responses were seen only sunitinib.•Effective therapies are needed to improve outcomes for this ultra-rare sarcoma type. BackgroundClear cell (CCS) a translocated aggressive malignancy high incidence metastases prognosis. There few studies describing in CCS. We report multi-institutional retrospective study within World Sarcoma Network (WSN).Materials...
Background Intimal sarcoma (InS) is an exceedingly rare neoplasm with unfavorable prognosis, for which new potentially active treatments are under development. We report on the activity of anthracycline‐based regimens, gemcitabine‐based and pazopanib in patients InS. Methods Seventeen reference centers Europe, United States, Japan contributed data to this retrospective analysis. Patients MDM2‐positive InS who were treated or between October 2001 January 2018 selected. Local pathological...
Background The objective of this study was to report on a retrospective series patients with epithelioid hemangioendothelioma (EHE) who received treatment sirolimus within the Italian Rare Cancer Network. Methods From January 2005, 38 adult advanced EHE continuous‐dosing sirolimus, 5 mg daily, until they developed either toxicity or disease progression. Disease progression in 6 months before start required. Each pathologic diagnosis reviewed. daily dose adjusted based plasma levels. Response...
The Clinical Trials Regulation EU 536/2014 (CTR) has presented challenges for adapting experimental centres. To address this regulatory change, in 2023, the Italian Sarcoma Group (ISG) established a Federated Trial Centre (FTC) model, including Research Coordinators (CRCs) and Nurses (RNs). explore CTR's impact, 40-question survey was launched April distributed among 48 FTC members from 27 institutions, with 30 responding. 46.6% of responders reported progress their institutions to...